Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Sells $77,200.00 in Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $1.93, for a total value of $77,200.00. Following the completion of the sale, the chairman now owns 1,331,543 shares of the company’s stock, valued at $2,569,877.99. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Neil Desai also recently made the following trade(s):

• On Monday, April 1st, Neil Desai sold 17,772 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.31, for a total value of $41,053.32.
• On Monday, March 4th, Neil Desai sold 14,964 shares of Aadi Bioscience stock. The shares were sold at an average price of $2.10, for a total value of $31,424.40.
• On Friday, March 1st, Neil Desai sold 27,036 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.97, for a total value of $53,260.92.
• On Thursday, February 1st, Neil Desai sold 42,000 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.74, for a total value of $73,080.00.

Aadi Bioscience Stock Performance

AADI stock opened at $2.02 on Friday. The company has a market capitalization of $49.59 million, a P/E ratio of -0.83 and a beta of 0.64. Aadi Bioscience, Inc. has a 52-week low of $1.55 and a 52-week high of $8.60. The business has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.78.

Aadi Bioscience (NASDAQ:AADI) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07. The business had revenue of $6.33 million during the quarter, compared to the consensus estimate of $6.46 million. Aadi Bioscience had a negative return on equity of 52.53% and a negative net margin of 270.04%. As a group, sell-side analysts forecast that Aadi Bioscience, Inc. will post -2.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aadi Bioscience

A hedge fund recently bought a new stake in Aadi Bioscience stock. Decheng Capital LLC bought a new position in Aadi Bioscience, Inc. (NASDAQ:AADI) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 526,329 shares of the company’s stock, valued at approximately $1,063,000. Aadi Bioscience comprises 0.3% of Decheng Capital LLC’s holdings, making the stock its 22nd largest holding. Decheng Capital LLC owned approximately 2.15% of Aadi Bioscience at the end of the most recent reporting period. 52.08% of the stock is owned by institutional investors.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.